Oramed Pharmaceuticals Investor Presentation — February 2020

Document content

Addressing the Multibillion -Dollar

Injectable Drug Markets with Oral

February 20202Safe Harbor

Certain statements contained inthis material areforward -looking statements .These forward -looking statements

arebased onthe current expectations ofthe management ofOramed only, and aresubject toanumber of

factors and uncertainties that could cause actual results todiffer materially from those described intheforward -

looking statements, including the risks and uncertainties related tothe progress, timing, cost, and results of

clinical trials and product development programs ;difficulties ordelays inobtaining regulatory approval orpatent

protection forourproduct candidates ;competition from other pharmaceutical orbiotechnology companies ;and

our ability toobtain additional funding required toconduct our research, development and commercialization

activities, and others, allofwhich could cause theactual results orperformance ofOramed todiffer materially

from those contemplated insuch forward -looking statements .Except asotherwise required bylaw, Oramed

undertakes noobligation topublicly release any revisions tothese forward -looking statements toreflect events

orcircumstances after thedate hereof ortoreflect theoccurrence ofunanticipated events .Foramore detailed

description oftherisks and uncertainties affecting Oramed, reference ismade toOramed's reports filed from

time totime with the Securities and Exchange Commission .which involve known and unknown risks,

uncertainties and other factors which may cause the actual results, performance orachievements ofthe

company, orindustry results, tobematerially different from any future results, performance orachievements

expressed orimplied bysuch forward -looking statements .Please refer tothe company's filings with the

Securities and Exchange Commission foracomprehensive listofrisk factors that could cause actual results,

performance orachievements ofthe company todiffer materially from those expressed orimplied insuch

forward -looking statements .Oramed undertakes noobligation toupdate orrevise any forward -looking

▪Proprietary oral protein delivery platform

▪Diabetes first -initially targeting the lucrative insulin market

▪Robust pipeline leveraging IP portfolio for additional

significant market opportunities

▪Strong financial position over $ 30.4 M in cash and

investments, no debt1

▪Experienced management team backed by world -class

▪Multiple value -creation events for 2020

Preview truncated — download the full document for the complete content.